BioSyent (RX) Scheduled to Post Quarterly Earnings on Thursday

BioSyent (CVE:RX) is scheduled to announce its earnings results after the market closes on Thursday, May 16th. Analysts expect the company to announce earnings of C$0.08 per share for the quarter.

BioSyent (CVE:RX) last issued its quarterly earnings data on Wednesday, March 13th. The company reported C$0.12 earnings per share for the quarter, missing analysts’ consensus estimates of C$0.17 by C($0.05). The firm had revenue of C$8.27 million during the quarter, compared to analyst estimates of C$8.80 million. BioSyent had a return on equity of 18.97% and a net margin of 20.45%.

BioSyent Trading Up 0.9 %

Shares of BioSyent stock opened at C$8.59 on Friday. The firm has a 50-day simple moving average of C$8.60 and a two-hundred day simple moving average of C$8.54. The company has a market cap of C$99.73 million, a P/E ratio of 16.21 and a beta of 0.93. BioSyent has a fifty-two week low of C$7.03 and a fifty-two week high of C$9.26. The company has a debt-to-equity ratio of 3.51, a quick ratio of 6.91 and a current ratio of 6.48.

Insider Buying and Selling

In other news, insider BioSyent Inc. acquired 5,100 shares of BioSyent stock in a transaction dated Monday, April 29th. The shares were acquired at an average cost of C$8.55 per share, for a total transaction of C$43,627.95. Insiders own 38.45% of the company’s stock.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.